Employees: 49
Size Eupraxia Pharmaceuticals (EPRX.TO) is a Canada Health Care company (Biotechnology) with a market value of $416M, the 352nd largest of 405 Canada companies the cockpit tracks. Shares closed at C$8.86 on 18 Nov 2026.
Performance Over six months the shares gained 1.4%, against -23.0% for the median peer and +1.1% for the Canada market (cap-weighted) — 3rd highest of 21 in its peer set.
Capital Return on invested capital runs 183.5 points below its cost of capital (10.5% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | C$0 | C$0 | C$0 | C$0 | C$0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -C$669,081 | -C$332,159 | -C$235,248 | -C$209,911 | -C$193,273 |
| EBITDA | -C$91.4M | -C$53.4M | -C$36.8M | -C$37.7M | -C$23.4M |
| Net income | -C$82.0M | -C$53.9M | -C$34.9M | -C$38.1M | -C$23.3M |
| Free cash flow | -C$62.6M | -C$40.7M | -C$41.2M | -C$28.0M | -C$19.1M |
| Capital expenditure | C$1.15M | C$822,929 | C$142,787 | C$99,036 | C$308,370 |
| Total debt | C$4.86M | C$211,592 | C$103,348 | C$13.8M | C$10.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EPRX.TO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.4% | -13.4% | 7th lowest of 21 |
| 6-month return | +1.4% | -23.0% | 3rd highest of 21 |
| Distance from 52-week high | -32.3% | -43.6% | 3rd highest of 21 |
| ROIC minus cost of capital | -183.5 pp | -9.3 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | 10.6× | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | 908.6× | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | 215.1× | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | 10.3× | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | 1.0× | -15.3% | +197.3% |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | 2.9× | 4.0% | -62.3% |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 14.6× | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 12.3× | 5.3% | +70.5% |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 1.9× | -18.8% | -36.1% |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 2.6× | -19.5% | n/a |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | 3.1× | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $402M | -22% | -17% | -16% | 10.9× | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 4.0× | 2.1% | +0.5% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $396M | -33% | n/a | n/a | n/a | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $395M | -41% | -30% | -27% | 5.2× | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 2.2× | 7.7% | +7.3% |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | 3.3× | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |